カテゴリ： Allied Market Research, 世界, 医療/バイオ

抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬

■ 英語タイトル：Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB250）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB250
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：220
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に171.3百万ドルであった世界の抗コクシジウム薬市場規模が、2031年までに257.8百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）4.2%で成長すると予測しています。本レポートは、抗コクシジウム薬の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、薬剤クラス別（イオノフォア、合成薬）分析、薬剤作用別（コクシジオスタット、殺真菌薬）分析、動物種類別（家禽、牛、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、boehringer ingelheim animal health - us、Ceva sante animale、Huvepharma EOOD、Merck & Co., Inc、Venkateshwara hatcheries Private Limitedなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の抗コクシジウム薬市場規模：薬剤クラス別
- イオノフォアの市場規模
- 合成薬の市場規模
・世界の抗コクシジウム薬市場規模：薬剤作用別
- コクシジオスタットにおける市場規模
- 殺真菌剤における市場規模
・世界の抗コクシジウム薬市場規模：動物種類別
- 家禽における市場規模
- 牛における市場規模
- その他における市場規模
・世界の抗コクシジウム薬市場規模：地域別
- 北米の抗コクシジウム薬市場規模
- ヨーロッパの抗コクシジウム薬市場規模
- アジア太平洋の抗コクシジウム薬市場規模
- 中南米・中東・アフリカの抗コクシジウム薬市場規模
・企業状況
・企業情報

世界の抗コクシジウム薬市場は、2021年に1億7,130万ドルと評価され、2022年から2031年までの年平均成長率は4.2%を記録し、2031年には2億5,780万ドルに達すると予測されています。

コクシジウム症は、Eimeria属の原虫寄生によって引き起こされる家禽の集団における最も一般的な病気の1つです。これらの原虫は、有性期と無性期を含む複雑なライフサイクルを持つ、義務的な細胞内寄生虫です。これらの寄生虫は腸に寄生し、他の病気（壊死性腸炎）にかかりやすくし、腸の栄養吸収能力を低下させます。この病気は、昆虫や野鳥のような機械的な媒介によって感染または伝播します。しかし、エイメリアの卵（オーシスト）は野鳥によって機械的に輸送される可能性があり、これらの寄生虫は宿主特異的であるため、野鳥は生物学的リザーバーにはなりません。従って、この病気は抗コクシジウム薬の助けを借りて制御することができます。ブロイラーのライフサイクルは短いため、コクシジウム殺虫剤のような寄生虫を殺す薬剤を使用することで、腸内からエイメリアを完全に除去することができます。

抗コクシジウム剤市場の成長は、先進的な抗コクシジウム剤の開発の増加、コクシジウム症やその治療薬に関する啓蒙のための政府イニシアチブの増加によって牽引されています。さらに、肉や牛乳などの動物性タンパク質食品の需要の高さ、抗コクシジウム薬の開発委託の増加、製薬業界やバイオテクノロジー業界の発展も市場の成長に貢献しています。しかし、家畜への抗コクシジウム薬の使用を制限する政府の厳しい規制や、コクシジウム症の治療にワクチンや漢方薬などの代替薬を使用することが、この市場の成長を妨げると予想されます。
逆に、手頃な価格で入手可能な新製品に対する意識の高まりは、市場に有利な機会を生み出すと予想されます。

世界の抗コクシジウム薬市場は、薬物クラス、薬物作用、動物の種類、地域に基づいてセグメント化されます。薬物クラス別では、市場はイオノフォアと合成薬に二分されます。薬物作用別では、市場はコクシジオスタティックとコクシジオシドに分類されます。動物種類別では、市場は家禽、牛、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

この市場に参入している主な市場プレイヤーには、Bayer AG、Boehringer Ingelheim International GmbH、Ceva sante animale、Dosh Pharmaceuticals Private Limited、Huvepharma EOOD、Merck & Co., Inc.、Venkateshwara hatcheries Private Limited、Vetoquinol SA、Virbac SA、Zoetis Inc.などがあります。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの抗コクシジウム薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、抗コクシジウム薬の市場機会を特定します。
・主な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・抗コクシジウム薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界の抗コクシジウム薬の市場動向、主要企業、市場セグメント、応用分野、市場成長戦略などの分析を収録しています。

〈主要市場セグメント〉
薬剤クラス別
イオノフォア
合成医薬品

薬剤作用別
抗コクシジウム剤
殺コクシジウム作用

動物の種類別
家禽
牛
その他

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
boehringer ingelheim animal health – us
Ceva sante animale
Huvepharma EOOD
Merck & Co., Inc
Venkateshwara hatcheries Private Limited
Dosh Pharmaceuticals
Vetoquinol SA
Virbac SA
Zoetis Inc
Bayer AG

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.2.Restraints
3.4.3.Opportunities
3.5.COVID-19 Impact Analysis on the market
CHAPTER 4: ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS
4.1 Overview
4.1.1 Market size and forecast
4.2 Ionophore
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Synthetic Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
CHAPTER 5: ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION
5.1 Overview
5.1.1 Market size and forecast
5.2 Coccidiostatic
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Coccidiocidal
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE
6.1 Overview
6.1.1 Market size and forecast
6.2 Poultry
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Cattle
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: ANTICOCCIDIAL DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Drug Class
7.2.3 North America Market size and forecast, by Drug Action
7.2.4 North America Market size and forecast, by Animal Type
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Drug Class
7.2.5.1.3 Market size and forecast, by Drug Action
7.2.5.1.4 Market size and forecast, by Animal Type
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Drug Class
7.2.5.2.3 Market size and forecast, by Drug Action
7.2.5.2.4 Market size and forecast, by Animal Type
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Drug Class
7.2.5.3.3 Market size and forecast, by Drug Action
7.2.5.3.4 Market size and forecast, by Animal Type
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Drug Class
7.3.3 Europe Market size and forecast, by Drug Action
7.3.4 Europe Market size and forecast, by Animal Type
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Drug Class
7.3.5.1.3 Market size and forecast, by Drug Action
7.3.5.1.4 Market size and forecast, by Animal Type
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Drug Class
7.3.5.2.3 Market size and forecast, by Drug Action
7.3.5.2.4 Market size and forecast, by Animal Type
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Drug Class
7.3.5.3.3 Market size and forecast, by Drug Action
7.3.5.3.4 Market size and forecast, by Animal Type
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Drug Class
7.3.5.4.3 Market size and forecast, by Drug Action
7.3.5.4.4 Market size and forecast, by Animal Type
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Drug Class
7.3.5.5.3 Market size and forecast, by Drug Action
7.3.5.5.4 Market size and forecast, by Animal Type
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Drug Class
7.3.5.6.3 Market size and forecast, by Drug Action
7.3.5.6.4 Market size and forecast, by Animal Type
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Drug Class
7.4.3 Asia-Pacific Market size and forecast, by Drug Action
7.4.4 Asia-Pacific Market size and forecast, by Animal Type
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Drug Class
7.4.5.1.3 Market size and forecast, by Drug Action
7.4.5.1.4 Market size and forecast, by Animal Type
7.4.5.2 China
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Drug Class
7.4.5.2.3 Market size and forecast, by Drug Action
7.4.5.2.4 Market size and forecast, by Animal Type
7.4.5.3 Australia
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Drug Class
7.4.5.3.3 Market size and forecast, by Drug Action
7.4.5.3.4 Market size and forecast, by Animal Type
7.4.5.4 India
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Drug Class
7.4.5.4.3 Market size and forecast, by Drug Action
7.4.5.4.4 Market size and forecast, by Animal Type
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Drug Class
7.4.5.5.3 Market size and forecast, by Drug Action
7.4.5.5.4 Market size and forecast, by Animal Type
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Drug Class
7.4.5.6.3 Market size and forecast, by Drug Action
7.4.5.6.4 Market size and forecast, by Animal Type
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Drug Class
7.5.3 LAMEA Market size and forecast, by Drug Action
7.5.4 LAMEA Market size and forecast, by Animal Type
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Drug Class
7.5.5.1.3 Market size and forecast, by Drug Action
7.5.5.1.4 Market size and forecast, by Animal Type
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Drug Class
7.5.5.2.3 Market size and forecast, by Drug Action
7.5.5.2.4 Market size and forecast, by Animal Type
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Drug Class
7.5.5.3.3 Market size and forecast, by Drug Action
7.5.5.3.4 Market size and forecast, by Animal Type
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Drug Class
7.5.5.4.3 Market size and forecast, by Drug Action
7.5.5.4.4 Market size and forecast, by Animal Type
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Top player positioning, 2021
8.5. Competitive Dashboard
8.6. Competitive Heatmap
8.7. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 boehringer ingelheim animal health – us
9.1.1 Company overview
9.1.2 Key Executives
9.1.3 Company snapshot
9.1.4 Operating business segments
9.1.5 Product portfolio
9.1.6 Business performance
9.1.7 Key strategic moves and developments
9.2 Ceva sante animale
9.2.1 Company overview
9.2.2 Key Executives
9.2.3 Company snapshot
9.2.4 Operating business segments
9.2.5 Product portfolio
9.2.6 Business performance
9.2.7 Key strategic moves and developments
9.3 Huvepharma EOOD
9.3.1 Company overview
9.3.2 Key Executives
9.3.3 Company snapshot
9.3.4 Operating business segments
9.3.5 Product portfolio
9.3.6 Business performance
9.3.7 Key strategic moves and developments
9.4 Merck & Co., Inc
9.4.1 Company overview
9.4.2 Key Executives
9.4.3 Company snapshot
9.4.4 Operating business segments
9.4.5 Product portfolio
9.4.6 Business performance
9.4.7 Key strategic moves and developments
9.5 Venkateshwara hatcheries Private Limited
9.5.1 Company overview
9.5.2 Key Executives
9.5.3 Company snapshot
9.5.4 Operating business segments
9.5.5 Product portfolio
9.5.6 Business performance
9.5.7 Key strategic moves and developments
9.6 Dosh Pharmaceuticals
9.6.1 Company overview
9.6.2 Key Executives
9.6.3 Company snapshot
9.6.4 Operating business segments
9.6.5 Product portfolio
9.6.6 Business performance
9.6.7 Key strategic moves and developments
9.7 Vetoquinol SA
9.7.1 Company overview
9.7.2 Key Executives
9.7.3 Company snapshot
9.7.4 Operating business segments
9.7.5 Product portfolio
9.7.6 Business performance
9.7.7 Key strategic moves and developments
9.8 Virbac SA
9.8.1 Company overview
9.8.2 Key Executives
9.8.3 Company snapshot
9.8.4 Operating business segments
9.8.5 Product portfolio
9.8.6 Business performance
9.8.7 Key strategic moves and developments
9.9 Zoetis Inc
9.9.1 Company overview
9.9.2 Key Executives
9.9.3 Company snapshot
9.9.4 Operating business segments
9.9.5 Product portfolio
9.9.6 Business performance
9.9.7 Key strategic moves and developments
9.10 Bayer AG
9.10.1 Company overview
9.10.2 Key Executives
9.10.3 Company snapshot
9.10.4 Operating business segments
9.10.5 Product portfolio
9.10.6 Business performance
9.10.7 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 2. ANTICOCCIDIAL DRUGS MARKET FOR IONOPHORE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. ANTICOCCIDIAL DRUGS MARKET FOR SYNTHETIC DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOSTATIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 6. ANTICOCCIDIAL DRUGS MARKET FOR COCCIDIOCIDAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 8. ANTICOCCIDIAL DRUGS MARKET FOR POULTRY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. ANTICOCCIDIAL DRUGS MARKET FOR CATTLE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. ANTICOCCIDIAL DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. ANTICOCCIDIAL DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 17. U.S. ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 20. CANADA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 23. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 26. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 33. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 34. FRANCE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 36. UK ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 37. UK ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 39. ITALY ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ITALY ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 42. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. SPAIN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 45. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 48. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 51. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 52. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 53. JAPAN ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CHINA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CHINA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 58. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 59. AUSTRALIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 62. INDIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. SOUTH KOREA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 67. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 70. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA ANTICOCCIDIAL DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 73. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 74. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH AFRICA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 83. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY DRUG ACTION, 2021-2031 (REVENUE, $MILLION)
TABLE 84. REST OF LAMEA ANTICOCCIDIAL DRUGS MARKET, BY ANIMAL TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY EXECUTIVES
TABLE 86.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: COMPANY SNAPSHOT
TABLE 87.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: OPERATING SEGMENTS
TABLE 88.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: PRODUCT PORTFOLIO
TABLE 89.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: NET SALES
TABLE 90.BOEHRINGER INGELHEIM ANIMAL HEALTH - US: KEY STRATERGIES
TABLE 92.CEVA SANTE ANIMALE: KEY EXECUTIVES
TABLE 92.CEVA SANTE ANIMALE: COMPANY SNAPSHOT
TABLE 93.CEVA SANTE ANIMALE: OPERATING SEGMENTS
TABLE 94.CEVA SANTE ANIMALE: PRODUCT PORTFOLIO
TABLE 95.CEVA SANTE ANIMALE: NET SALES
TABLE 96.CEVA SANTE ANIMALE: KEY STRATERGIES
TABLE 98.HUVEPHARMA EOOD: KEY EXECUTIVES
TABLE 98.HUVEPHARMA EOOD: COMPANY SNAPSHOT
TABLE 99.HUVEPHARMA EOOD: OPERATING SEGMENTS
TABLE 100.HUVEPHARMA EOOD: PRODUCT PORTFOLIO
TABLE 101.HUVEPHARMA EOOD: NET SALES
TABLE 102.HUVEPHARMA EOOD: KEY STRATERGIES
TABLE 104.MERCK & CO., INC: KEY EXECUTIVES
TABLE 104.MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 105.MERCK & CO., INC: OPERATING SEGMENTS
TABLE 106.MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 107.MERCK & CO., INC: NET SALES
TABLE 108.MERCK & CO., INC: KEY STRATERGIES
TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY EXECUTIVES
TABLE 110.VENKATESHWARA HATCHERIES PRIVATE LIMITED: COMPANY SNAPSHOT
TABLE 111.VENKATESHWARA HATCHERIES PRIVATE LIMITED: OPERATING SEGMENTS
TABLE 112.VENKATESHWARA HATCHERIES PRIVATE LIMITED: PRODUCT PORTFOLIO
TABLE 113.VENKATESHWARA HATCHERIES PRIVATE LIMITED: NET SALES
TABLE 114.VENKATESHWARA HATCHERIES PRIVATE LIMITED: KEY STRATERGIES
TABLE 116.DOSH PHARMACEUTICALS: KEY EXECUTIVES
TABLE 116.DOSH PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 117.DOSH PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 118.DOSH PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 119.DOSH PHARMACEUTICALS: NET SALES
TABLE 120.DOSH PHARMACEUTICALS: KEY STRATERGIES
TABLE 122.VETOQUINOL SA: KEY EXECUTIVES
TABLE 122.VETOQUINOL SA: COMPANY SNAPSHOT
TABLE 123.VETOQUINOL SA: OPERATING SEGMENTS
TABLE 124.VETOQUINOL SA: PRODUCT PORTFOLIO
TABLE 125.VETOQUINOL SA: NET SALES
TABLE 126.VETOQUINOL SA: KEY STRATERGIES
TABLE 128.VIRBAC SA: KEY EXECUTIVES
TABLE 128.VIRBAC SA: COMPANY SNAPSHOT
TABLE 129.VIRBAC SA: OPERATING SEGMENTS
TABLE 130.VIRBAC SA: PRODUCT PORTFOLIO
TABLE 131.VIRBAC SA: NET SALES
TABLE 132.VIRBAC SA: KEY STRATERGIES
TABLE 134.ZOETIS INC: KEY EXECUTIVES
TABLE 134.ZOETIS INC: COMPANY SNAPSHOT
TABLE 135.ZOETIS INC: OPERATING SEGMENTS
TABLE 136.ZOETIS INC: PRODUCT PORTFOLIO
TABLE 137.ZOETIS INC: NET SALES
TABLE 138.ZOETIS INC: KEY STRATERGIES
TABLE 140.BAYER AG: KEY EXECUTIVES
TABLE 140.BAYER AG: COMPANY SNAPSHOT
TABLE 141.BAYER AG: OPERATING SEGMENTS
TABLE 142.BAYER AG: PRODUCT PORTFOLIO
TABLE 143.BAYER AG: NET SALES
TABLE 144.BAYER AG: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
  • 群発頭痛のグローバル市場（2021～2031）：反復発作性、慢性
  • 経口抗ウィルス薬のグローバル市場（2021-2031）：肝炎、ヒト免疫不全ウイルス（HIV）、インフルエンザ、その他
  • 坐骨神経痛治療のグローバル市場（2021～2031）：急性坐骨神経痛、慢性坐骨神経痛、その他
  • 白血病治療薬のグローバル市場（2021-2031）：急性リンパ球性白血病、急性骨髄性白血病、慢性リンパ球性白血病、慢性骨髄性白血病、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB250 )"抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬" (英文：Anticoccidial Drugs Market By Drug Class (Ionophore, Synthetic Drugs), By Drug Action (Coccidiostatic, Coccidiocidal), By Animal Type (Poultry, Cattle, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。